Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06062810 | Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | recruiting | Phase 3 | 246 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| 1 |
| Apr 23, 2026 |
| clinicaltrials |
| NCT04595565 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer(SASCIA) | active not recruiting | Phase 3 | 1,332 | GBG Forschungs GmbHOTHER | 7 | Apr 22, 2026 | clinicaltrials |
| NCT02525211 | Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment | terminated | Phase 3 | 59 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03927027 | Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection | active not recruiting | Phase 3 | 534 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04732598 | A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer(AMBITION) | completed | Phase 3 | 281 | Japanese Foundation for Cancer ResearchOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05780567 | Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | active not recruiting | Phase 3 | 1,946 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06195709 | ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients(ECLECTIC) | recruiting | Phase 3 | 300 | Institut CurieOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04085276 | Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment(TORCHLIGHT) | completed | Phase 3 | 531 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07533123 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | recruiting | Phase 3 | 364 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT02311959 | Therapeutic Nipple Sparing Mastectomy.(MAPAM-01) | completed | Phase 3 | 450 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04650581 | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor(FINER) | active not recruiting | Phase 3 | 250 | Canadian Cancer Trials GroupNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer | recruiting | Phase 3 | 1,800 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT04851613 | Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | active not recruiting | Phase 3 | 256 | Laekna LimitedINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT05514054 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer(EMBER-4) | active not recruiting | Phase 3 | 8,000 | Eli Lilly and CompanyINDUSTRY | 31 | Apr 2, 2026 | clinicaltrials |
| NCT07340658 | A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer(SIE-3) | not yet recruiting | Phase 3 | 300 | Rovi Pharmaceuticals LaboratoriesINDUSTRY | 0 | Apr 2, 2026 | clinicaltrials |
| NCT03315364 | Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy(OPTIMAL) | active not recruiting | Phase 2 / Phase 3 | 549 | Daehwa Pharmaceutical Co., Ltd.INDUSTRY | 5 | Apr 1, 2026 | clinicaltrials |
| NCT06954961 | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 3 | 640 | InventisBio Co., LtdINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT00003140 | Letrozole After Tamoxifen in Treating Women With Breast Cancer | completed | Phase 3 | 5,187 | NCIC Clinical Trials GroupNETWORK | 2 | Mar 27, 2026 | clinicaltrials |
| NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | recruiting | Phase 3 | 544 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05806060 | Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer(BCTOP-T-M01) | recruiting | Phase 3 | 134 | Fudan UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07294508 | A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer | recruiting | Phase 2 / Phase 3 | 706 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy(PLANET) | not yet recruiting | Phase 3 | 1,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT02089100 | Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer(STEREO-SEIN) | active not recruiting | Phase 3 | 154 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483996 | Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer(CRYSTAL) | not yet recruiting | Phase 3 | 938 | Franciscus Gasthuis & Vlietland (Hospital)OTHER | 0 | Mar 19, 2026 | clinicaltrials |
| NCT05654623 | A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer(VERITAC-2) | active not recruiting | Phase 3 | 624 | PfizerINDUSTRY | 31 | Mar 18, 2026 | clinicaltrials |
| NCT00893061 | Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer(MNEMOSYNE) | completed | Phase 3 | 44 | Centre Oscar LambretOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06767527 | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | recruiting | Phase 3 | 416 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01480869 | Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients(VITACAL) | completed | Phase 3 | 215 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07467330 | Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment | recruiting | Phase 3 | 258 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 12, 2026 | clinicaltrials |
| NCT01349322 | Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery | active not recruiting | Phase 3 | 2,354 | Radiation Therapy Oncology GroupNETWORK | 8 | Mar 5, 2026 | clinicaltrials |
| NCT04494425 | Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer(DB-06) | active not recruiting | Phase 3 | 866 | AstraZenecaINDUSTRY | 28 | Mar 4, 2026 | clinicaltrials |
| NCT02767661 | Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer(MECCA) | completed | Phase 3 | 263 | Sun Yat-sen UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03523585 | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | completed | Phase 3 | 608 | Daiichi SankyoINDUSTRY | 15 | Feb 27, 2026 | clinicaltrials |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer | recruiting | Phase 3 | 540 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03414970 | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer | active not recruiting | Phase 3 | 898 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 24, 2026 | clinicaltrials |
| NCT05316324 | A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction | active not recruiting | Phase 3 | 353 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT02000622 | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.(OlympiAD) | completed | Phase 3 | 302 | AstraZenecaINDUSTRY | 19 | Feb 13, 2026 | clinicaltrials |
| NCT06585969 | A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer(DISCORDANT) | withdrawn | Phase 3 | 0 | Danish Breast Cancer Cooperative GroupOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07406542 | A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | not yet recruiting | Phase 3 | 400 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT07407517 | Adjuvant Intensification for LAR(POLARIS) | not yet recruiting | Phase 3 | 904 | Fudan UniversityOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06135714 | Metastasis-directed Therapy for Oligometastases of Breast Cancer(OLIGAMI) | recruiting | Phase 3 | 340 | Tokyo Medical and Dental UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07385365 | A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer | not yet recruiting | Phase 3 | 3,142 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer(e3) | active not recruiting | Phase 3 | 1,939 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)(VIKTORIA-1) | active not recruiting | Phase 3 | 701 | Celcuity IncINDUSTRY | 23 | Feb 10, 2026 | clinicaltrials |
| NCT05909397 | Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer(VERITAC-3) | active not recruiting | Phase 3 | 59 | PfizerINDUSTRY | 10 | Feb 10, 2026 | clinicaltrials |
| NCT06009627 | Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients | completed | Phase 2 / Phase 3 | 119 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2026source: clinicaltrials